Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer

Inclusion Criteria:

• Age of 18-70 years
• Patients with histologically or cytologically confirmed Non-Small Cell Lung Cancer
• Patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage not available to any of resectable surgery or radiotherapy.
• Patients with measurable lesions
• Eatern Cooperative Oncolgy Group status 0 to 2.
• Life expectancy >/= 5 months

• Patients with adequate organ(heart, kidney, liver)and bone marrow function, as defined by

  1. Absolute neutrophil count >/= 1.5 x 10^9/L, Platelet count >/= 100 x 10^9/L
  2. Total bilirubin </= upper limit of normal
  3. Aspartate Aminotransferase and/or Alanine Aminotransferase </= 2 x upeer limit of normal
  4. creatinine </= 1.5 x upeer limit of normal
• Patients who have signed the informed consent form.

Exclusion Criteria:

• Female volunteers admitted to the study must be using a reliable means of contraception
• Received radiation therapy within 6 weeks before randomization
• Known brain or spinal cord metastases
• Have acute infection
• Have active infection or serious concomitant systemic disorder incompatible with the study
• Presence or history of malignancy other than Non-Small Cell Lung Cancer
• Have severe neurologic or psychological disorder
• Patients who have to receive other chemo-radiotherapy or immunotherapy
• Patients who have received chemotherapy within the previous 30 days
• Patients who are candidates for combined modality treatment.
• Patients who have participated in a clinical study within the previous 30 days